AbbVie Inc. $ABBV Position Reduced by Bokf Na

Key Points

• Bokf Na trimmed its stake in AbbVie (NYSE:ABBV) by 6.9%, selling 16,266 shares to hold 220,743 shares valued at about $50.44 million, making AbbVie 0.8% of its portfolio and its 26th largest position.
• AbbVie beat Q1 expectations (EPS $2.65 vs. $2.59; revenue $15.0B vs. $14.72B), raised 2026 guidance and saw a stock rally as investor attention grew around Skyrizi, Rinvoq and the pipeline.
• AbbVie declared a quarterly dividend of $1.73 ($6.92 annualized) for a yield of about 3.4%, though its payout ratio is very high at roughly 341%.

Bokf Na cut its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 6.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 220,743 shares of the company's stock after selling 16,266 shares during the quarter. AbbVie accounts for 0.8% of Bokf Na's portfolio, making the stock its 26th largest position. Bokf Na's holdings in AbbVie were worth $50,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter valued at about $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at about $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie in the 3rd quarter valued at about $31,000. WestEnd Advisors LLC grew its holdings in AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Finally, Caitlin John LLC acquired a new position in AbbVie during the third quarter valued at approximately $33,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger‑than‑expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top‑searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Dividend appeal remains strong: Multiple income‑focused outlets continue to list AbbVie as a high‑yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
• Neutral Sentiment: Positive clinical and real‑world data showcased at DDW: AbbVie presented long‑term and real‑world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life‑science AI forums signals digital investment but is unlikely to move near‑term fundamentals. Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
• Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near‑term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns (April 23)

AbbVie Stock Performance

Shares of NYSE ABBV opened at $206.12 on Wednesday. The stock has a market cap of $364.46 billion, a PE ratio of 101.54, a PEG ratio of 0.72 and a beta of 0.32. The business has a fifty day moving average of $214.17 and a two-hundred day moving average of $221.34. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts' expectations of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The business's revenue was up 12.4% on a year-over-year basis. During the same period last year, the business earned $2.46 earnings per share. Analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie's dividend payout ratio (DPR) is presently 340.89%.

Wall Street Analyst Weigh In

Several brokerages have commented on ABBV. Piper Sandler lowered their price target on AbbVie from $299.00 to $294.00 and set an "overweight" rating on the stock in a report on Thursday, April 23rd. Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Barclays assumed coverage on AbbVie in a research report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price for the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Citigroup reduced their target price on AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research report on Tuesday, January 27th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $252.90.

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by company insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.